{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Semax",
    "short_name": "Semax",
    "aliases": [],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Semax is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is reported, including in regions where it has been marketed/used clinically (often intranasal) and in gray-market contexts elsewhere. Product quality and labeling vary in non-regulated markets, increasing uncertainty."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Overall risk uncertainty is driven by heterogeneous clinical literature (often region-specific), variability in formulations/routes in real-world use, and limited large, modern, independently replicated trials for many claimed outcomes. Potential risks include neuropsychiatric effects, interactions with other CNS-active substances, and unknown long-term safety in adolescents.",
      "developmental_systems_of_concern": [
        "cns",
        "neurodevelopment",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Semax is a synthetic peptide based on a fragment of ACTH, developed to influence neurotrophic and neuromodulatory pathways in the brain. Published literature includes mechanistic work and clinical reports for cognition/neurologic recovery contexts, but evidence quality varies and many claims lack large, independent replication.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a synthetic peptide based on a fragment of ACTH, developed to influence neurotrophic and neuromodulatory pathways in the brain",
        "training recovery support",
        "muscle performance and endurance interest",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      },
      {
        "id": "E2",
        "title": "[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax].",
        "source_type": "review",
        "source_id": "PMID:18379501",
        "evidence_grade": "human_observational",
        "year": 2007,
        "url": "https://pubmed.ncbi.nlm.nih.gov/18379501/",
        "notes": "Clinical literature is region-specific and heterogeneous; use for boundaries, not claims inflation."
      },
      {
        "id": "E3",
        "title": "[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].",
        "source_type": "journal_article",
        "source_id": "PMID:29798983",
        "evidence_grade": "animal",
        "year": 2018,
        "url": "https://pubmed.ncbi.nlm.nih.gov/29798983/",
        "notes": "Supports mechanism discussion only; not proof of human benefit."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Semax",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:11:26.845496+00:00",
        "change_type": "content_update",
        "summary": "Filled Semax core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. language from key descriptive fields and added a minimal evidence scaffold. No protocols/dosing/instructions added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-19T16:47:10.573738+00:00",
        "change_type": "content_update",
        "summary": "Curation update: section structure standardized; content review pending. No protocols or instructions are provided.",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_cognition_mood"
      ]
    },
    "slug": "semax"
  },
  "canonical_name": "Semax",
  "interactions": {
    "drug_classes": [
      "ssri-snri-serotonergic"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "benefits": [],
    "side_effects_common": [],
    "side_effects_serious": [],
    "who_should_be_cautious": [],
    "bottom_line": "Pep-Talk curation pending. We avoid speculative claims; this section will be populated with practical, real-world benefits and known side effects as evidence is reviewed."
  }
}
